Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Short term Debt: 2016-2018

  • Niagen Bioscience's Short term Debt fell 55.81% to $137,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $137,000, marking a year-over-year decrease of 55.81%. This contributed to the annual value of $137,000 for FY2018, which is 55.81% down from last year.
  • As of Q4 2018, Niagen Bioscience's Short term Debt stood at $137,000, which was down 55.81% from $310,000 recorded in Q4 2017.
  • Over the past 5 years, Niagen Bioscience's Short term Debt peaked at $1.5 million during Q1 2016, and registered a low of $137,000 during Q4 2018.
  • Over the past 3 years, Niagen Bioscience's median Short term Debt value was $327,000 (recorded in 2016), while the average stood at $579,894.
  • Data for Niagen Bioscience's Short term Debt shows a maximum YoY slumped of 77.50% (in 2016) over the last 5 years.
  • Niagen Bioscience's Short term Debt (Quarterly) stood at $344,000 in 2016, then declined by 9.88% to $310,000 in 2017, then slumped by 55.81% to $137,000 in 2018.
  • Its last three reported values are $137,000 in Q4 2018, $310,000 for Q4 2017, and $344,000 during Q4 2016.